BOSTON—After achieving pathologic complete response for esophageal cancer, recurrence is more common in adenocarcinoma than in squamous cell carcinoma, a new study has concluded.
The investigation also found that both clinical tumor and node stage prior to neoadjuvant therapy were associated with the rate of cancer recurrence.
“Neoadjuvant chemoradiation has become standard care for esophageal cancer that is considered locoregional in extent based on the pivotal CROSS trial and other